Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial
Authors:
- Roger S. McIntyreRMRoger S. McIntyre
- Miriam CohenMCMiriam Cohen
- Jun ZhaoJZJun Zhao
- Larry AlphsLALarry Alphs
- Thomas A. MacekTMThomas A. Macek
- John PanagidesJPJohn Panagides
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 122 (1-2) , 27-38
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Merck
This publication has 44 references indexed in Scilit:
- Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for changeBipolar Disorders, 2008
- Efficacy and Tolerability of Asenapine in Acute SchizophreniaThe Journal of Clinical Psychiatry, 2007
- Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United KingdomJournal of Psychopharmacology, 2007
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approachesPharmaceutical Statistics, 2007
- The armamentarium of treatments for bipolar disorder: a review of the literatureInternational Journal of Neuropsychopharmacology, 2006
- Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorderThe British Journal of Psychiatry, 2005
- Metabolic risk during antipsychotic treatmentClinical Therapeutics, 2004
- Depressive symptoms in acute schizophreniaProgress in Neuro-Psychopharmacology, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978